Arcus Biosciences (RCUS) Tops Q2 EPS by 6c

Arcus Biosciences (NYSE: RCUS) reported Q2 EPS of ($1.04), $0.06 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $29 million versus the consensus estimate of $31.81 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture downgraded by TD Cowen on AI concerns
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM